KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Cash Flow (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Net Cash Flow for 15 consecutive years, with -$17.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 175.71% year-over-year to -$17.5 million, compared with a TTM value of $32.2 million through Dec 2025, up 2432.15%, and an annual FY2025 reading of $32.2 million, up 2432.15% over the prior year.
  • Net Cash Flow was -$17.5 million for Q4 2025 at Travere Therapeutics, down from $35.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $171.7 million in Q4 2023 and bottomed at -$148.8 million in Q3 2023.
  • Average Net Cash Flow over 5 years is -$2.4 million, with a median of -$4.1 million recorded in 2024.
  • The sharpest move saw Net Cash Flow surged 1275.15% in 2021, then tumbled 218.9% in 2022.
  • Year by year, Net Cash Flow stood at -$41.6 million in 2021, then grew by 8.01% to -$38.3 million in 2022, then soared by 548.3% to $171.7 million in 2023, then tumbled by 86.55% to $23.1 million in 2024, then crashed by 175.71% to -$17.5 million in 2025.
  • Business Quant data shows Net Cash Flow for TVTX at -$17.5 million in Q4 2025, $35.6 million in Q3 2025, and $11.3 million in Q2 2025.